Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk.
The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the US, and many more elsewhere, the ordeal and expense of these drugs.
“The impact is tremendous,” said the study leader, Joseph Sparano of Montefiore Medical Center in New York. Most women in this situation don’t need treatment beyond surgery and hormone therapy, he said.
Photo: AP
The study was funded by the National Cancer Institute, some foundations and proceeds from the US breast cancer postage stamp. Results were discussed Sunday at an American Society of Clinical Oncology conference in Chicago and published by the New England Journal of Medicine. Some study leaders consult for breast cancer drugmakers or for the company that makes the gene test.
MOVING AWAY FROM CHEMO
Cancer care has been evolving away from chemotherapy — older drugs with harsh side effects — in favor of gene-targeting therapies, hormone blockers and immune system treatments. When chemo is used now, it’s sometimes for shorter periods or lower doses than it once was.
For example, another study at the conference found that Merck’s immunotherapy drug Keytruda worked better than chemo as initial treatment for most people with the most common type of lung cancer, and with far fewer side effects.
The breast cancer study focused on cases where chemo’s value increasingly is in doubt: women with early-stage disease that has not spread to lymph nodes, is hormone-positive (meaning its growth is fueled by estrogen or progesterone) and is not the type that the drug Herceptin targets.
The usual treatment is surgery followed by years of a hormone-blocking drug. But many women also are urged to have chemo to help kill any stray cancer cells. Doctors know that most don’t need it, but evidence is thin on who can forgo it.
The study gave 10,273 patients a test called Oncotype DX, which uses a biopsy sample to measure the activity of genes involved in cell growth and response to hormone therapy, to estimate the risk that a cancer will recur.
WHAT THE STUDY FOUND
About 17 percent of women had high-risk scores and were advised to have chemo. The 16 percent with low-risk scores now know they can skip chemo, based on earlier results from this study.
The new results are on the 67 percent of women at intermediate risk. All had surgery and hormone therapy, and half also got chemo.
After nine years, 94 percent of both groups were still alive, and about 84 percent were alive without signs of cancer, so adding chemo made no difference.
Certain women 50 or younger did benefit from chemo; slightly fewer cases of cancer spreading far beyond the breast occurred among some of them given chemo, depending on their risk scores on the gene test.
WILL PEOPLE TRUST THE RESULTS?
All women like those in the study should get gene testing to guide their care, said Richard Schilsky, chief medical officer of the oncology society. Oncotype DX costs around US$4,000, which Medicare and many insurers cover. Similar tests including one called MdusammaPrint also are widely used.
Testing solved a big problem of figuring out who needs chemo, said Harold Burstein of the Dana-Farber Cancer Institute in Boston. Many women think “if I don’t get chemotherapy I’m going to die, and if I get chemo I’m going to be cured,” but the results show there’s a sliding scale of benefit and sometimes none, he said.
Lisa Carey, a breast specialist at the University of North Carolina’s Lineberger Comprehensive Cancer Center, said she would be very comfortable advising patients to skip chemo if they were like those in the study who did not benefit from it.
Jennifer Litton at MD Anderson Cancer Center in Houston, agreed, but said: “Risk to one person is not the same thing as risk to another. There are some people who say, ‘I don’t care what you say, I’m never going to do chemo,’” and won’t even have the gene test, she said. Others want chemo for even the smallest chance of benefit.
Adine Usher, 78, who lives in Hartsdale, New York, joined the study 10 years ago at Montefiore and was randomly assigned to the group given chemo.
“I was a little relieved. I sort of viewed chemo as extra insurance,” she said. The treatments “weren’t pleasant,” she concedes. Her hair fell out, she developed an infection and was hospitalized for a low white blood count, “but it was over fairly quickly and I’m really glad I had it.”
If doctors had recommended she skip chemo based on the gene test, “I would have accepted that,” she said. “I’m a firm believer in medical research.”
No one saw it coming. Everyone — including the Chinese Nationalist Party (KMT) — expected at least some of the recall campaigns against 24 of its lawmakers and Hsinchu Mayor Ann Kao (高虹安) to succeed. Underground gamblers reportedly expected between five and eight lawmakers to lose their jobs. All of this analysis made sense, but contained a fatal flaw. The record of the recall campaigns, the collapse of the KMT-led recalls, and polling data all pointed to enthusiastic high turnout in support of the recall campaigns, and that those against the recalls were unenthusiastic and far less likely to vote. That
Behind a car repair business on a nondescript Thai street are the cherished pets of a rising TikTok animal influencer: two lions and a 200-kilogram lion-tiger hybrid called “Big George.” Lion ownership is legal in Thailand, and Tharnuwarht Plengkemratch is an enthusiastic advocate, posting updates on his feline companions to nearly three million followers. “They’re playful and affectionate, just like dogs or cats,” he said from inside their cage complex at his home in the northern city of Chiang Mai. Thailand’s captive lion population has exploded in recent years, with nearly 500 registered in zoos, breeding farms, petting cafes and homes. Experts warn the
A couple of weeks ago the parties aligned with the People’s Republic of China (PRC), the Chinese Nationalist Party (KMT) and the Taiwan People’s Party (TPP), voted in the legislature to eliminate the subsidy that enables Taiwan Power Co (Taipower) to keep up with its burgeoning debt, and instead pay for universal cash handouts worth NT$10,000. The subsidy would have been NT$100 billion, while the cash handout had a budget of NT$235 billion. The bill mandates that the cash payments must be completed by Oct. 31 of this year. The changes were part of the overall NT$545 billion budget approved
The unexpected collapse of the recall campaigns is being viewed through many lenses, most of them skewed and self-absorbed. The international media unsurprisingly focuses on what they perceive as the message that Taiwanese voters were sending in the failure of the mass recall, especially to China, the US and to friendly Western nations. This made some sense prior to early last month. One of the main arguments used by recall campaigners for recalling Chinese Nationalist Party (KMT) lawmakers was that they were too pro-China, and by extension not to be trusted with defending the nation. Also by extension, that argument could be
RSS